Trade Regulus Therapeutics Inc. - RGLS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023624% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001401% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.76 |
| Open | 1.69 |
| 1-Year Change | -39.21% |
| Day's Range | 1.67 - 1.95 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 1, 2025 | 1.76 | 0.07 | 4.14% | 1.69 | 2.02 | 1.64 |
| Mar 31, 2025 | 1.72 | 0.01 | 0.58% | 1.71 | 1.81 | 1.64 |
| Mar 28, 2025 | 1.72 | 0.25 | 17.01% | 1.47 | 1.72 | 1.47 |
| Mar 27, 2025 | 1.47 | 0.08 | 5.76% | 1.39 | 2.02 | 1.32 |
| Mar 26, 2025 | 1.26 | -0.04 | -3.08% | 1.30 | 1.32 | 1.25 |
| Mar 25, 2025 | 1.28 | -0.09 | -6.57% | 1.37 | 1.37 | 1.28 |
| Mar 24, 2025 | 1.41 | 0.02 | 1.44% | 1.39 | 1.45 | 1.38 |
| Mar 21, 2025 | 1.35 | 0.00 | 0.00% | 1.35 | 1.37 | 1.33 |
| Mar 20, 2025 | 1.33 | -0.03 | -2.21% | 1.36 | 1.38 | 1.30 |
| Mar 19, 2025 | 1.38 | 0.03 | 2.22% | 1.35 | 1.40 | 1.31 |
| Mar 18, 2025 | 1.35 | 0.00 | 0.00% | 1.35 | 1.42 | 1.30 |
| Mar 17, 2025 | 1.34 | -0.13 | -8.84% | 1.47 | 1.49 | 1.34 |
| Mar 14, 2025 | 1.45 | 0.11 | 8.21% | 1.34 | 1.53 | 1.34 |
| Mar 13, 2025 | 1.36 | -0.02 | -1.45% | 1.38 | 1.45 | 1.33 |
| Mar 12, 2025 | 1.45 | 0.13 | 9.85% | 1.32 | 1.47 | 1.27 |
| Mar 11, 2025 | 1.30 | -0.02 | -1.52% | 1.32 | 1.36 | 1.30 |
| Mar 10, 2025 | 1.31 | 0.02 | 1.55% | 1.29 | 1.33 | 1.29 |
| Mar 7, 2025 | 1.26 | -0.04 | -3.08% | 1.30 | 1.33 | 1.26 |
| Mar 6, 2025 | 1.35 | 0.05 | 3.85% | 1.30 | 1.39 | 1.30 |
| Mar 5, 2025 | 1.34 | 0.06 | 4.69% | 1.28 | 1.36 | 1.28 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Regulus Therapeutics Inc. Company profile
About Regulus Therapeutics Inc
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases. Its product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a kidney disease. The Company completed Phase I multiple-ascending dose (MAD) clinical trial. RGLS4326, an anti-miR targeting miR-17, is for the treatment of autosomal dominant polycystic kidney disease (ADPKD). It is in Phase I clinical trial. The Company’s pre-clinical pipeline candidates include RGLS5579 and anti-miR-132. RGLS5579 is developing for the treatment of Glioblastoma and anti-miR-132 is developing for the treatment of non-alcoholic steatohepatitis. Its developing two undisclosed products under Cell Therapies program and Hepatitis B virus program.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Regulus Therapeutics Inc revenues decreased from $10M to $0K. Net loss increased 77% to $27.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects research increase of 16% to $16.5M (expense), general increase of 15% to $7.9M (expense), Stock-based Compensation in SGA increase of 9% to $2.1M (expense).
Equity composition
Common stock $.001 Par, 10/12, 200M auth., 34,130,393 issd. Insider Owns 67.04%.
| Industry: | Bio Therapeutic Drugs |
Suite 210
3545 John Hopkins Court
92121
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com